Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Barinthus Biotherapeutics PLC Sponsored ADR stock logo
BRNS
Barinthus Biotherapeutics
$1.12
-4.7%
$1.24
$0.64
$2.92
$45.60M-0.7331,701 shs7,765 shs
Eupraxia Pharmaceuticals Inc. stock logo
EPRX
Eupraxia Pharmaceuticals
$5.36
+1.7%
$5.30
$2.20
$6.20
$192.75M1.57,734 shs16,816 shs
Korro Bio, Inc. stock logo
KRRO
Korro Bio
$23.08
-2.5%
$15.74
$10.29
$98.00
$216.74M2.51137,119 shs189,912 shs
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
$18.48
-1.9%
$20.39
$2.03
$14.36
$173.68M1.1150,104 shs94,969 shs
7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Barinthus Biotherapeutics PLC Sponsored ADR stock logo
BRNS
Barinthus Biotherapeutics
0.00%-5.55%-24.05%+6.04%-11.84%
Eupraxia Pharmaceuticals Inc. stock logo
EPRX
Eupraxia Pharmaceuticals
0.00%+1.52%-0.74%+36.39%+104.58%
Korro Bio, Inc. stock logo
KRRO
Korro Bio
0.00%+15.17%+54.28%+100.35%-53.82%
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
-1.91%-7.55%-14.76%+8.64%-48.31%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Barinthus Biotherapeutics PLC Sponsored ADR stock logo
BRNS
Barinthus Biotherapeutics
3.1461 of 5 stars
3.53.00.00.03.80.81.3
Eupraxia Pharmaceuticals Inc. stock logo
EPRX
Eupraxia Pharmaceuticals
2.2029 of 5 stars
3.61.00.00.02.50.00.6
Korro Bio, Inc. stock logo
KRRO
Korro Bio
1.5448 of 5 stars
3.61.00.00.03.10.00.0
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Barinthus Biotherapeutics PLC Sponsored ADR stock logo
BRNS
Barinthus Biotherapeutics
3.00
Buy$3.00166.90% Upside
Eupraxia Pharmaceuticals Inc. stock logo
EPRX
Eupraxia Pharmaceuticals
3.17
Buy$11.00105.22% Upside
Korro Bio, Inc. stock logo
KRRO
Korro Bio
3.29
Buy$86.83276.23% Upside
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest BRNS, KRRO, EPRX, and NLTX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/20/2025
Eupraxia Pharmaceuticals Inc. stock logo
EPRX
Eupraxia Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$12.00
8/13/2025
Korro Bio, Inc. stock logo
KRRO
Korro Bio
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$25.00
8/13/2025
Korro Bio, Inc. stock logo
KRRO
Korro Bio
Raymond James Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetStrong-Buy ➝ Strong-Buy$153.00 ➝ $147.00
8/13/2025
Korro Bio, Inc. stock logo
KRRO
Korro Bio
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$100.00 ➝ $90.00
7/24/2025
Eupraxia Pharmaceuticals Inc. stock logo
EPRX
Eupraxia Pharmaceuticals
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$11.00
7/24/2025
Korro Bio, Inc. stock logo
KRRO
Korro Bio
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$100.00
6/26/2025
Eupraxia Pharmaceuticals Inc. stock logo
EPRX
Eupraxia Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$12.00
6/26/2025
Eupraxia Pharmaceuticals Inc. stock logo
EPRX
Eupraxia Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$12.00
6/16/2025
Eupraxia Pharmaceuticals Inc. stock logo
EPRX
Eupraxia Pharmaceuticals
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageSpeculative Buy
(Data available from 8/31/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Barinthus Biotherapeutics PLC Sponsored ADR stock logo
BRNS
Barinthus Biotherapeutics
$14.97M3.06N/AN/A$2.52 per share0.45
Eupraxia Pharmaceuticals Inc. stock logo
EPRX
Eupraxia Pharmaceuticals
N/AN/AN/AN/A($0.30) per shareN/A
Korro Bio, Inc. stock logo
KRRO
Korro Bio
$2.27M95.47N/AN/A$12.26 per share1.88
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
N/AN/AN/AN/A$11.08 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Barinthus Biotherapeutics PLC Sponsored ADR stock logo
BRNS
Barinthus Biotherapeutics
-$61.07M-$1.73N/AN/AN/AN/A-54.70%-44.75%11/5/2025 (Estimated)
Eupraxia Pharmaceuticals Inc. stock logo
EPRX
Eupraxia Pharmaceuticals
-$25.50M-$0.85N/AN/AN/AN/A-367.73%-126.38%11/6/2025 (Estimated)
Korro Bio, Inc. stock logo
KRRO
Korro Bio
-$83.58M-$9.75N/AN/AN/AN/A-61.51%-42.87%11/11/2025 (Estimated)
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
-$57.56M-$3.11N/AN/AN/A-37.22%-30.91%N/A

Latest BRNS, KRRO, EPRX, and NLTX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/12/2025Q2 2025
Eupraxia Pharmaceuticals Inc. stock logo
EPRX
Eupraxia Pharmaceuticals
-$0.21-$0.26-$0.05-$0.26N/AN/A
8/12/2025Q2 2025
Korro Bio, Inc. stock logo
KRRO
Korro Bio
-$2.54-$2.74-$0.20-$2.74$0.41 million$1.46 million
8/7/2025Q2 2025
Barinthus Biotherapeutics PLC Sponsored ADR stock logo
BRNS
Barinthus Biotherapeutics
-$0.29-$0.52-$0.23-$0.52N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Barinthus Biotherapeutics PLC Sponsored ADR stock logo
BRNS
Barinthus Biotherapeutics
N/AN/AN/AN/AN/A
Eupraxia Pharmaceuticals Inc. stock logo
EPRX
Eupraxia Pharmaceuticals
N/AN/AN/AN/AN/A
Korro Bio, Inc. stock logo
KRRO
Korro Bio
N/AN/AN/AN/AN/A
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Barinthus Biotherapeutics PLC Sponsored ADR stock logo
BRNS
Barinthus Biotherapeutics
N/A
7.89
7.89
Eupraxia Pharmaceuticals Inc. stock logo
EPRX
Eupraxia Pharmaceuticals
N/A
8.72
8.72
Korro Bio, Inc. stock logo
KRRO
Korro Bio
N/A
5.98
5.98
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
N/A
15.33
15.33

Institutional Ownership

CompanyInstitutional Ownership
Barinthus Biotherapeutics PLC Sponsored ADR stock logo
BRNS
Barinthus Biotherapeutics
25.20%
Eupraxia Pharmaceuticals Inc. stock logo
EPRX
Eupraxia Pharmaceuticals
N/A
Korro Bio, Inc. stock logo
KRRO
Korro Bio
13.18%
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
52.37%
CompanyEmployeesShares OutstandingFree FloatOptionable
Barinthus Biotherapeutics PLC Sponsored ADR stock logo
BRNS
Barinthus Biotherapeutics
10740.72 million36.36 millionN/A
Eupraxia Pharmaceuticals Inc. stock logo
EPRX
Eupraxia Pharmaceuticals
2935.96 millionN/AN/A
Korro Bio, Inc. stock logo
KRRO
Korro Bio
709.39 million8.96 millionNo Data
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
909.40 million9.25 millionNo Data

Recent News About These Companies

(NGNE) Proactive Strategies
Neurogene concludes merger deal with Neoleukin Therapeutics
Neoleukin Therapeutics Announces 1-for-4 Reverse Stock Split
Pre-market Movers: ORTX, CMBM, GROM, RSVR, FEMY…
Neoleukin Therapeutics Announces 1-for-5 Reverse Stock Split
Neoleukin Therapeutics Recent Insider Activity

New MarketBeat Followers Over Time

Media Sentiment Over Time

Barinthus Biotherapeutics stock logo

Barinthus Biotherapeutics NASDAQ:BRNS

$1.12 -0.06 (-4.72%)
Closing price 08/29/2025 03:58 PM Eastern
Extended Trading
$1.12 0.00 (-0.36%)
As of 08/29/2025 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer. It is also involved in the development of partnered candidates, such as AB-729-202, which is under phase 2a studies for the treatment of patients with chronic HBV infection; VTP-600, an immunotherapy candidate under phase 1 studies as a potential treatment for NSCLC in combination with standard of care treatment, chemotherapy, and pembrolizumab; VTP-500, a prophylactic vaccine product candidate under phase 1 studies to prevent infection and subsequent disease caused by the MERS coronavirus; and VTP-400, a prophylactic vaccine candidate under phase 1 studies to prevent shingles in adults aged 50 years and older. In addition, the company offers Vaxzevria (formerly VTP-900 and AZD1222), a prophylactic vaccine for the prevention of COVID-19 Infection. Further, it has license, research and development, and collaboration agreements with OUI, NIH, IMC, CanSino, CRUK; VOLT; and Arbutus. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Didcot, the United Kingdom.

Eupraxia Pharmaceuticals stock logo

Eupraxia Pharmaceuticals NASDAQ:EPRX

$5.36 +0.09 (+1.71%)
Closing price 08/29/2025 03:59 PM Eastern
Extended Trading
$5.54 +0.18 (+3.26%)
As of 08/29/2025 07:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company's lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee. Eupraxia Pharmaceuticals Inc. is based in VICTORIA, BC.

Korro Bio stock logo

Korro Bio NASDAQ:KRRO

$23.08 -0.59 (-2.49%)
Closing price 08/29/2025 04:00 PM Eastern
Extended Trading
$23.06 -0.02 (-0.11%)
As of 08/29/2025 05:38 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Korro Bio, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, OPERA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe alcohol-associated hepatitis, and other subsets of pain. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.

Neoleukin Therapeutics stock logo

Neoleukin Therapeutics NASDAQ:NLTX

$18.48 -0.36 (-1.91%)
As of 08/29/2025

Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.